Advisory Board

Rear Admiral (Ret.) Richard J. Bertin, PhD., RPh

Rear Admiral (Ret.) Richard Bertin is Executive Director of Board of Pharmaceutical Specialties (BPS). He has held this position since February 1997, when he retired from the United States Public Health Service after a long career and a variety of clinical and administrative positions.

A 1965 graduate of the University of Pittsburgh with a Bachelor of Science in Pharmacy, RADM Dr. Bertin earned a Master’s Degree in Hospital Pharmacy and a Ph.D. in Pharmacy Administration from the University of Minnesota. While in the Public Health Service, he served as Chief Professional Officer (as an Assistant Surgeon General at the grade of Rear Admiral) as well as in the National Institute of Mental Health, the Bureau of Medical Services, the Office of the Assistant Secretary for Health, the Office of the Surgeon General, and the Food and Drug Administration. His responsibilities ranged from clinical pharmacy practice to advising the Surgeon General, the Assistant Secretary for Health, and other Federal and non-Federal leaders on national pharmacy issues.

BPS was established in 1976 by the American Pharmacists Association to recognize specialties and to certify pharmacists’ knowledge and skills in specialized areas of pharmacy practice. Five of the specialties are currently recognized by BPS: nuclear pharmacy, nutrition support pharmacy, oncology pharmacy, pharmacotherapy, and psychiatric pharmacy. Nearly 5000 pharmacists are currently certified by BPS in one or more of these specialties. As the Board’s first Executive Director, RADM Dr. Bertin is responsible for the overall management and growth of the BPS specialty certification program. In his present position, he works with several national membership organizations and educational institutions on a wide variety of credentialing activities across pharmacy profession.

Charles Daniels, PhD, MS

Dr. Daniels is a professor and Associate Dean for Clinical Affairs, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego.

Dr. Daniels’ research focus has been in pharmacoeconomics, safe medication systems, medication use quality, and quality pharmacy patient care. His recent work has evaluated the role of technologies in medication error reduction and patient-pharmacist interaction. His group is also examining use of multi-hospital data in the drug costs and improved outcomes. Dr. Daniels is a founding member of the Steering Committee for the Pharmacoeconomics Forum at the UC San Diego.

Education: B.S. in Pharmacy, 1975 the Univ. of Arizona; M.S. 1978 Univ. of Minnesota; Ph.D. in Social and Administrative Pharmacy 1981 Univ. of Minnesota; Pharmacy Resident 1976 the NIH Clinical Center.

Awards & Honors: NIH Clinical Center Director’s Award 1999 & 2003; Recognition as one of the 50 Most Influential Pharmacists; the Best-Practices in Health-System Pharmacy Management Award for Chemotherapy Errors Prevention Task Force 2000; AFPE Fellow 1980; ASHP Fellow in 1993; NIH grant and contract reviews.

Leadership Experience: Associate Dean of Clinical Affairs and Pharmacist-In-Chief at the Skaggs School of Pharmacy, UC San Diego since 2004 Chief of the Pharmacy Department of NIH Clinical Center 1995-2004; Director of Graduate Studies in Hospital Pharmacy, Univ. of Minnesota.

Enrique Fefer, PhD., MS

Dr. Fefer served as Director of the International Affairs Program of the U.S. Pharmacopeia (USP) from August 2000 to January 2004. The program was initiated to support USP’s international efforts with other national Pharmacopeias, international organizations and regulatory agencies. After his departure, he retained ties to USP, serving, since its inception (2004 – present), as Chairman of the Advisory Panel for the Spanish translation of the Pharmacopeia, and, during the 2005-2010 cycle, as a member of the International Health Expert Committee and the Council of the Convention.

Prior to joining USP Dr. Fefer was Program Coordinator for Essential Drugs and Technology in the Pan American Health Organization (PAHO) WHO Regional Office for the Americas, with responsibility for projects in pharmaceuticals, public health labs, blood banks, radiological health services & medical equipment and devices. He was granted Honorary Membership in 2000 for his work and the promotion of USP – PAHO activities in Latin America.

Before joining the PAHO, Dr. Fefer worked for the U.S. FDA, Office of New Drug Evaluation as a Sr Pharmacologist and he served on various Agency committees and task forces concerned with pre-clinical drug testing.

Born in Bogota Colombia, Dr. Fefer studied at Bar Illan University in Israel and Yeshvia University in New York city. He earned an MS in chemistry and PhD in pharmacology from University of Miami FL.

Robert I. Field, PhD, MPH, JD

Professor, Department of Health Management and Policy

Dr. Robert Field is a nationally known expert on health law and on public health whose research focuses on ethical issues in managed care, public policy and legal facets of health care reform and genetic screening. He holds a joint appointment as Professor of Law at the Earle Mack School of Law at Drexel University.

Dr. Field is author of Health Care Regulation in America: Complexity, Confrontation and Compromise, a comprehensive guide to the government’s role in regulating health care in the United States. He previously taught at University of the Sciences in Philadelphia where he founded and chaired the Dept. of Health Policy and Public Health and directed the Graduate Program in Health Policy.

Previously, Professor Field led business planning and development for the primary care network of University of Pennsylvania Health System, where he was in charge of acquisitions of physician practices that created the network and directed other business development activities. He has also con-ducted health policy research at the Institute of Medicine of the National Academy of Sciences and the Center for Law and Health Sciences at Boston University and practiced health law with Ballard Spahr Andrews & Ingersoll, Philadelphia. He is a senior fellow of Leonard Davis Institute of Health Economics at the University of Pennsylvania and a member of the adjunct faculty of the Wharton School.

Professor Field earned a PhD from Boston University and a MPH from the Harvard University School of Public Health. He received his JD from the Columbia University School of Law, where he was associate editor of the Columbia Journal of Environmental Law. Professor Field graduated magna cum laude and received his AB from Harvard College.

Albert J. Finestone, MD, MS

Associate Dean of CME, Professor of Medicine Emeritus, Temple University

Educational Background:

BA, Temple University, Philadelphia, PA, 1942

MD, MSc, Temple University, Philadelphia, PA, 1945-1951

Residency, Internal Medicine, Temple University Hospital, Philadelphia, PA

Internship, Temple University Hospital, Philadelphia, PA

Fellowship, Pathology, Georgetown University Medical Center, Washington, DC

Clinical Interests:

• Geriatrics

• Continuing Medical Education

Board Certification(s):

• Internal Medicine

• Additional qualifications in geriatric medicine

Professional Affiliations:

• Fellow, American College of Physicians

• Fellow, College of Physicians of Philadelphia

• Member, Misstate and Local Medical Society

• American Psychosomatic Society

• Society for Academic Continuing Medical Education

Charles-LaudadioCharles Laudadio, MD, MBA

Former Global Medical Affairs Director


Dr. Laudadio recently retired from CSL Behring where he had been a Global Medical Director of Medical Affairs for the past five years. Prior to this, he spent twenty years in clinical research and seven years in medical affairs several large and small pharma/biotech companies.

During his time in the pharmaceutical business, he has been involved in BLAs, NDAs (505B1 and 505B2) and ANDAs while developing/supporting drugs and biologics with various delivery systems including IV, subcutaneous, immediate release oral, extended release oral, transdermal, topical, patch, and buccal/transmucosal drug in all phases of clinical research from I-IV.

While in medical affairs, Dr. Laudadio has been involved in many activities including Investigator Initiated Studies, Education and Publication Plans KOL development, Copy Review, Advisory Board Meetings, Safety Review, Registry Studies, etc. His primary areas of expertise are in Diabetic Complications, Urology, Pain Management and Plasma derived products related to coagulation and hereditary angioedema.

Dr. Laudadio received a BS in Electrical Engineering from the Polytechnic Institute of NY, his MD from the University of Louisville and his MBA in the Executive MBA program at West Chester University. His former medical training was in urology.

Bryan Liang, MD, PhD, JD

California Western School of Law

J.D. Harvard University

M.D. Columbia University

Ph.D. University of Chicago

B.S. Massachusetts Institute of Technology

Professor Liang is a prolific scholar and outstanding teacher who has authored or co-authored five books and over 300 articles on a range of health law and policy topics. He is well known for policy work in the interface between law, medicine, economic incentive structures, public health, and of patient safety, and serves on the editorial boards of several journals, including Journal of Clinical Anesthesia, Journal of Patient Safety, Hospital Physician, Survey of Anesthesiology, Quality and Safety in Health Care, Journal of Biolaw and Business, and the National Faculty of Core Content Review of Family Medicine. He also serves on several important law and policy bodies, including the American Bar Association Advisor for National Conference on Commissioners of State Laws in Emergency Preparedness and Response, the Secretary of the U.S. Department of Health and Human Services Advisory Committee on Minority Health, Board of Directors of National Committee for the Prevention of Elder Abuse, and as Vice President of the Partnership for Safe Medicines.

Professor Liang is also an Adjunct Associate Professor of Public Health, the College of Health and Human Services, San Diego State University.

Eucharia Nnadi, RPh, JD, PhD


Roseman University of Health Sciences, NV

Ex-Dean, Howard University School of Pharmacy

Dr. Eucharia E. Nnadi is Vice President for Academic Affairs and Program Planning at University of Southern Nevada. Prior to joining University of Southern Nevada she served as Vice President for Academic Affairs at the University of Maryland Eastern Shore (UMES), from 1997 to 2002. She came to UMES from Howard University where she served as Dean of the College of Pharmacy and Pharmaceutical Sciences. She began her academic career as Assistant Professor of Pharmacy Administration at College of Pharmacy and Pharmaceutical Sciences, Florida A&M University Tallahassee in 1981. She became the first female full professor at FAMU College of Pharmacy and Pharmaceutical Sciences. Dr. Nnadi became the first black female Dean for a US College/School of Pharmacy in 1994.

Dr. Nnadi earned a BS degree in Pharmacy, cum laude from Creighton University in Nebraska, MS degree in Hospital Pharmacy, and PhD degree in Social and Administrative Pharmacy from University of Minnesota. She received her JD degree in Law with high honors from the College of Law at Florida State University. She has received train-ing in Dispute Resolution Using Mediation, Total Quality Management, Leadership Training and Fundraising to name a few.

Dr. Nnadi is an experienced and accomplished teacher, researcher and prolific writer. She has taught numerous courses to graduate and under-graduate students. She served as principal or co-investigator on grants totaling more than a million dollars. She authored/co-authored many articles, abstracts, chapters in textbooks, and a textbook

Dr. Nnadi received numerous honors and awards and is a member of several national professional organizations and serves/served on several national professional committees.

Frank Palumbo, PhD, JD, RPh

Professor and Executive Director, University of Maryland School of Pharmacy Center on Drugs and Public Policy. He is a member of the Maryland Bar and a licensed pharmacist and has practiced both pharmacy and law.

Originally from Scranton, PA, Professor Palumbo received a BS in pharmacy from Medical University of South Carolina, and an MS and a PhD in Health Care Administration from the University of Mississippi. He received a JD from the University Baltimore School of Law. He practiced food and drug law during his sabbatical year at Hyman, Phelps and McNamara in Washington, D.C.

Dr. Palumbo is executive director of the Center on Drugs and Public Policy at University of Maryland School of Pharmacy. In addition to his research, teaching and administration at School of Pharmacy, he also serves as adjunct professor in UMB’s School of Law, where he teaches food and drug law.

Dr. Palumbo has long been a recognized expert in the area of pharmacy law and policy. He is the president of ASPL. The mission of the ASPL is to educate the pharmacist-attorneys, pharmacists, attorneys and other interested parties on various legal issues that affect pharmacy. For the public, ASPL also provides an attorney referral service linking with lawyers who are expert in pharmacy law, and an expert witness program.

Peter Howard Rheinstein, MD, JD

Dr. Rheinstein received a B.S. with high honors from Michigan State University, an M.S. in mathematics from Michigan State University, an M.D. from Johns Hopkins University, and a J.D. from the University of Maryland School of Law.

Dr. Rheinstein MD, JD, MS, currently consults and speaks on drug issues. Previously, he was the senior vice president for medical and clinical matters at a Johns Hopkins spinoff firm develop-ing cancer diagnostics and therapeutics, publisher of the journal Discovery Medicine, and director of several offices for the U.S. Food and Drug Ad-ministration. At the FDA, he was director of the Drug Advertising and Labeling Division; he was acting deputy director Office of Drugs, acting director Office of Drugs; director Office of Drug Standards, and as director medicine staff Office Health Affairs. While at FDA, he developed precedents for FDA regulation of prescription drug promotion, initiated FDA’s first patient medication information program; implemented the Drug Price Competition and Patent Term Restoration Act of 1984, and authored medication goals for Healthy People 2000 and 2010.

Dr. Rheinstein also has been practicing physician, medical school faculty member, medical director for a national chain of extended care facilities and president of Drug Information Association (DIA). He has served APPI as its vice president for American Medical Association (AMA) Relations and delegate to the AMA House of Delegates, as vice chair of the Policy Committee (and of ACRP Government Affairs Committee), and president of the Baltimore-Washington Chapter. He received the APPI President’s Outstanding Service Award in 2003.